March 3, 2020 / 12:24 PM / a month ago

BRIEF-Hutchison China MediTech Says Covid-19 Outbreak Posing Some Challenges To Operations In China

March 3 (Reuters) - Hutchison China MediTech Ltd:

* FINAL RESULTS AND CLINICAL UPDATE

* COVID-19 OUTBREAK IS POSING SOME CHALLENGES TO OPERATIONS RESULTING FROM RESTRICTIONS ON MOVEMENT IN CHINA

* TO-DATE, NONE OF CO’S MANUFACTURING OPERATIONS IN CHINA HAVE BEEN MATERIALLY AFFECTED

* AT THIS STAGE UNABLE TO ASSESS LONG-TERM EFFECT OF COVID-19 OUTBREAK, IF ANY

* FY GROUP REVENUE OF $204.9 MILLION (2018: $214.1M)

* FY NET LOSS ATTRIBUTABLE TO CHI-MED OF $106.0 MILLION (2018: NET LOSS OF $74.8M)

* ASSUMES AT THIS STAGE THAT FINANCIAL IMPACT OF RECENT COVID-19 OUTBREAK WILL NOT BE MATERIAL TO GROUP

* EXPECT TO START MANY GLOBAL REGISTRATION STUDIES THIS YEAR WITH FRUQUINTINIB, SURUFATINIB, POTENTIALLY SAVOLITINIB Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below